Literature DB >> 3418728

Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta.

R L Hornung1, H A Young, W J Urba, R H Wiltrout.   

Abstract

The investigational drug flavone acetic acid (FAA) systemically augments natural killer (NK) cell activity in normal and tumor-bearing mice and in human cancer patients. The results from the present investigation demonstrate that in vivo administration of FAA induces in a dose-dependent manner high levels of serum interferon (IFN) within 4 hours in BALB/c, C57BL/6, and BALB/c nude mice. Antibody neutralization studies indicated that FAA induced IFN of the alpha/beta type, while molecular hybridization studies demonstrated that FAA rapidly stimulated the production of IFN alpha mRNA in splenic leukocytes. In vivo administration of anti-IFN alpha/beta antibodies to FAA-treated mice inhibited the FAA-induced augmentation of splenic NK cell activity at 4 hours. These results suggest that FAA mediates its anti-tumor effects indirectly by immunomodulation as well as directly by antiproliferative or cytotoxic activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3418728     DOI: 10.1093/jnci/80.15.1226

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  12 in total

1.  Editorial: One small molecule: a new way to treat the flu?

Authors:  Howard Young
Journal:  J Leukoc Biol       Date:  2011-03       Impact factor: 4.962

2.  A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.

Authors:  I N Olver; L K Webster; J F Bishop; K H Stokes
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.

Authors:  L M Ching; M J McKeage; W R Joseph; P Kestell; L J Zwi; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Species-specific detection of the antiviral small-molecule compound CMA by STING.

Authors:  Taner Cavlar; Tobias Deimling; Andrea Ablasser; Karl-Peter Hopfner; Veit Hornung
Journal:  EMBO J       Date:  2013-04-19       Impact factor: 11.598

5.  Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro.

Authors:  G G Chabot; M C Bissery; A Gouyette
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.

Authors:  L M Ching; W R Joseph; L Zhuang; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.

Authors:  D J Kerr; T Maughan; E Newlands; G Rustin; N M Bleehen; C Lewis; S B Kaye
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

8.  Flavone acetic acid--an interesting novel therapeutic agent or just another disappointment?

Authors:  M C Bibby
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

9.  Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.

Authors:  A K Ghosh; M Mellor; J Prendiville; N Thatcher
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

10.  Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft.

Authors:  G Pratesi; C Manzotti; M Tortoreto; R A Audisio; F Zunino
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.